RT Journal Article
SR Electronic
T1 Interaction of a Thrombin Inhibitor and a Platelet GP IIb/IIIa Antagonist <em>In Vivo</em>: Evidence That Thrombin Mediates Platelet Aggregation and Subsequent Thromboxane A<sub>2</sub> Formation During Coronary Thrombolysis
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 1178
OP 1185
VO 281
IS 3
A1 Domenico Pratico
A1 Natalie P. Murphy
A1 Desmond J. Fitzgerald
YR 1997
UL http://jpet.aspetjournals.org/content/281/3/1178.abstract
AB We examined the effect of a specific thrombin inhibitor, Ro 46-6240, alone and combined with an antagonist of the platelet GP IIb/IIIa, Ro44-9883, on the response to tissue-type plasminogen activator in a canine model of thrombolysis. Platelet activity was determined by measuring the excretion of 2,3-dinor-thromboxane (TX)B2, an enzymatic metabolite of TXA2. Ro 46-6240 administered before tissue-type plasminogen activator induced a dose-dependent prolongation of the activated partial thromboplastin time and prothrombin time. The time to reperfusion decreased dose-dependently (P &lt; .01) to 10 ± 6 min vs. 52 ± 5 min in controls. Ro 46-6240 also prevented reocclusion, which occurred in every case in control experiments. Urinary excretion of 2,3-dinor-TXB2 increased from 3 ± 1 to 37 ± 9 ng/mg creatinine in controls after reperfusion. This increase was reduced in a dose-dependent fashion by Ro 46-6240, such that at the highest dose, urinary 2,3-dinor-TXB2 after reperfusion was 5.6 ± 1 ng/mg creatinine. Similar functional and biochemical effects were seen when a subthreshold dose of Ro 46-6240 was combined with Ro 44-9883. At the dose used, Ro 44-9883 alone abolished platelet aggregation ex vivo but failed to modify the response to tissue-type plasminogen activator or the excretion of 2,3-dinor-TXB2 after reperfusion (51 ± 6 ng/mg creatinine, n = 3). However, the combination of Ro 44-9883 and Ro 46-6240 reduced the time to reperfusion (40 ± 8vs. 68 ± 15 min; n = 7, P &lt; .05), prevented reocclusion and abolished the rise in urinary 2,3-dinor-TXB2 (5 ± 1 ng/mg creatinine,n = 4). These findings suggest that thrombin mediates platelet activation during coronary thrombolysis. The increased platelet activity results in platelet aggregation and a subsequent increase in TXA2 formation. The American Society for Pharmacology and Experimental Therapeutics